medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2022, Number 2

<< Back Next >>

Rev Med UV 2022; 22 (2)

Early-onset colorrectal carcinoma in a third-level hospital:

Montiel-Jarquín ÁJ, Baltazar-Ramos JI, Pérez-Corro MÁ, López BCA

Language: Spanish
References: 32
Page: 7-24
PDF size: 383.78 Kb.


ABSTRACT

Introduction: Cancer is a high-impact disease, malignant tumors have positioned themselves as the leading causes of mortality for several decades, in Mexico more than 85,000 deaths occurred from this cause. Colorectal cancer is the third most frequent neoplasia and the second cause of death secondary to cancer. Objective: To know the prevalence and histopathological characteristics of colorectal carcinoma in men under 45 years of age. Material and methods: Direct research in the pathological archive of the UMAE HEP and use of the SPSS program. All men diagnosed with colorectal carcinoma under 45 years of age, diagnosed at this center, from 2014-2019 were included; Patients without a diagnosis of colorectal carcinoma or who were not part of the histopathological file were excluded. They were categorized by histological type, degree of differentiation, lymphovascular and perineural invasion, and lymph node invasion. Ethical aspects: study without risk. Results: 65,325 histopathological studies were analyzed, finding 128 patients with a diagnosis of colorectal carcinoma and a prevalence of 0.19%, 122 (95.3%) were adenocarcinomas and 6 (4.68%) squamous cell carcinomas of the anal region. Only 55 cases had a complete histopathological report, 46 (83.6%) adenocarcinomas usual or with production of mucus, 3(5.5%) adenocarcinomas with sig- net ring cells, 1(1.8%) squamous cell carcinoma of the anal region and 5(9.1%) intestinal- type adenocarcinomas of the anal region. Conclusions: An unequivocal definition of "early-onset colorectal cancer" is necessary, since there is no clear or widely accepted consensus available in the literature, our mean presentation time was 37.2 years and a prevalence of 0.19%; Also finding a correlation between lymphovascular invasion and the presence of lymph node metastases.


REFERENCES

  1. Adloff, M., Arnaud, J.-P., Schloegel, M., Thibaud, D., & Roberto, B. (1985).Clinicopathological features of colorrectal cancer in patients under40 years of age. International Journal of Colorrectal Disease, 25(7), 823–828. https://doi.org/10.1007/s00384-010-0914-9

  2. Aldaco-Sarvide, F., Pérez-Pérez, P., Cervantes-Sánchez, G., Torrecillas-Torres, L., Erazo-Valle-Solís, A. A., Cabrera-Galeana, P., Motola-Kuba, D., Anaya, P., Rivera-Rivera, S., & Cárdenas-Cárdenas,E. (2018). Mortality from cancer in Mexico: 2015 update.Gaceta Mexicana de Oncologia, 17(1), 28–34. https://doi.org/10.24875/j.gamo.M18000105

  3. Allende-lópez, A., & Fajardo-Gutiérrez, A. (2011). Historia del registrode cáncer en México. Revista Medica del Instituto Mexicano DelSeguro Social, 49(1), 27–32.

  4. Brau-Figueroa, H., Palafox-Parrilla, E. A., & Mohar-Betancourt, A.(2020). The national cancer registry in Mexico, a reality. GacetaMexicana de Oncologia, 19(2), 1–5. https://doi.org/10.24875/j.gamo.20000030

  5. Burbano Luna, D. F., Manrique, M. A., Chávez García, M. Á., Pérez Corona,T., Hernández Velázquez, N. N., Escandón Espinoza, Y. M.,Gómez Urrutia, J. M., Rubalcaba Macías, E. J., Martínez Ramírez,G., Cisneros, A. A., García Romero, A., Martínez Galindo, M. G.,& Cerna Cardona, J. (2016). Epidemiología del cáncer colorrectalen menores de 50 años en el Hospital Juárez de México.Endoscopia, 28(4), 160–165. https://doi.org/10.1016/j.endomx.2016.10.008

  6. Cáncer colorrectal: datos estadísticos sobre el cáncer. (2023). https://seer.cancer.gov/statfacts/html/colorect.html

  7. Castells, A., Balaguer, F., Gonzalo, V., & Castellví-Bel, S. (2007). Ciclooxigenasa2 y cáncer colorrectal: implicaciones terapéuticas.Gastroenterología y Hepatología, 30(5), 280–284. https://doi.org/10.1157/13101980

  8. Chang, D. T., Pai, R. K., Rybicki, L. A., Dimaio, M. A., Limaye, M., Jayachandran,P., Koong, A. C., Kunz, P. A., Fisher, G. A., Ford, J. M.,Welton, M., Shelton, A., Ma, L., Arber, D. A., & Pai, R. K. (2012).Clinicopathologic and molecular features of sporadic early-onsetcolorrectal adenocarcinoma: An adenocarcinoma with frequentsignet ring cell differentiation, rectal and sigmoid involvement,and adverse morphologic features. Modern Pathology, 25(8),1128–1139. https://doi.org/10.1038/modpathol.2012.61

  9. Dakubo, J. C. B., Naaeder, S. S. B., & Gyasi, R. K. (2014). Clinicopathologicalaspects of adenocarcinoma of the large bowel in a lowincidence population. Journal of Surgical Oncology, 109(3), 245–249. https://doi.org/10.1002/jso.23489

  10. Delgado-González, P., Said-Fernández, S., García-González, I. S., Garza-Treviño, E. N., Padilla-Rivas, G. R., Flores-Gutiérrez, J. P.,Muñoz-Maldonado, G. E., Treviño-Lozano, M. A., González-Guerrero,J. F., & Martínez-Rodríguez, H. G. (2016). Cáncer colorrectalen Nuevo León: factores de riesgo, hallazgos clínicos y cambiosen el desempeño físico de los pacientes a los 12 meses de postcirugía.Salud Publica de Mexico, 58(6), 592–594. https://doi.org/10.21149/spm.v58i6.7762

  11. Flossmann, E., & Rothwell, P. M. (2007). Effect of aspirin on long-termrisk of colorrectal cancer: consistent evidence from randomisedand observational studies. Lancet (London, England), 369(9573),1603–1613. https://doi.org/10.1016/S0140-6736(07)60747-8

  12. García-Rodríguez, L. A., & Huerta-Alvarez, C. (2001). Reduced risk of colorrectalcancer among long-term users of aspirin and nonaspirinnonsteroidal antiinflammatory drugs. Epidemiology (Cambridge,Mass.), 12(1), 88–93. https://doi.org/10.1097/00001648-200101000-00015

  13. Iriñiz, A. M., Bentolilla, G. A., & Ferreira Mongelos, P. A. (2009). Cáncercolorrectal en pacientes menores de 40 años: La edad comovariable del pronóstico. Revista Mexicana de Coloproctología,15(2), 1616–1226. www.medigraphic.org.mx

  14. Koh, K. S., Telisinghe, P. U., Bickle, I., Abdullah, M. S., Chong, C. F., &Chong, V. H. (2015). Characteristics of young colorrectal cancer in Brunei Darussalam: An epidemiologic study of 29 years(1986-2014). Asian Pacific Journal of Cancer Prevention, 16(8),3279–3283. https://doi.org/10.7314/APJCP.2015.16.8.3279

  15. Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021).Genetic and biological hallmarks of colorrectal cancer. Genes &Development, 35(11–12), 787–820. https://doi.org/10.1101/gad.348226.120

  16. Limaiem, F., Azzabi, S., Sassi, A., Mzabi, S., & Bouraoui, S. (2018). Colorrectalcancer in young adults: A retrospective study of 32 tunisianpatients. Pan African Medical Journal, 31, 1–9. https://doi.org/10.11604/pamj.2018.31.62.11043

  17. Mantilla-Morales, A., Mendoza-Morales, R. C., & Alvarado-Cabrero, I.(2014). Evaluación de piezas quirúrgicas con carcinoma de colon.Gaceta Mexicana de Oncologia, 13(4), 229–235.

  18. Mauri, G., Sartore-Bianchi, A., Russo, A. G., Marsoni, S., Bardelli, A.,& Siena, S. (2019). Early-onset colorrectal cancer in young individuals.Molecular Oncology, 13(2), 109–131. https://doi.org/10.1002/1878-0261.12417

  19. Meneses-García, A., Ruiz-Godoy, L. M., Beltrán-Ortega, A., Sánchez-Cervantes,F., Tapia-Conyer, R., & Mohar, A. (2012). Principales neoplasiasmalignas en México y su distribución geográfica (1993-2002). Revista de Investigacion Clinica, 64(4), 322–329.

  20. Morales, C., & Peinado, M. A. (2006). Inestabilidad de microsatélites:Papel diagnóstico e implicaciones pronósticas. Gastroenterologiay Hepatologia Continuada, 5(1), 18–22. https://doi.org/10.1016/S1578-1550(06)74271-1

  21. Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher,P., Washington, K. M., Carneiro, F., & Cree, I. A. (2020).The 2019 WHO classification of tumours of the digestive system.Histopathology, 76(2), 182–188. https://doi.org/10.1111/his.13975

  22. Pai, R. K., Jayachandran, P., Koong, A. C., Chang, D. T., Kwok, S., Ma, L.,Arber, D. A., Balise, R. R., Tubbs, R. R., Shadrach, B., & Pai, R. K.(2012). BRAF-mutated, microsatellite-stable adenocarcinomaof the proximal colon: An aggressive adenocarcinoma with poorsurvival, mucinous differentiation, and adverse morphologic features.American Journal of Surgical Pathology, 36(5), 744–752.https://doi.org/10.1097/PAS.0b013e31824430d7

  23. Parsons, M. T., Buchanan, D. D., Thompson, B., Young, J. P., & Spurdle, A. B.(2012). Correlation of tumour BRAF mutations and MLH1 methylationwith germline mismatch repair (MMR) gene mutationstatus: a literature review assessing utility of tumour featuresfor MMR variant classification. Journal of Medical Genetics, 49(3),151–157. https://doi.org/10.1136/jmedgenet-2011-100714

  24. Pila Pérez, R., Pila Peláez, R., Suárez Sorí, B., & Rodríguez López, A.(2000). Carcinoma colorrectal en pacientes menores de cuarentaaños. NEOPLASIAS COLORRECTALES, 1, 68–70.

  25. Reynoso-Noverón, N., & Mohar, A. (2014). El cáncer en México: Propuestaspara su control. Salud Publica de Mexico, 56(5), 527–532.

  26. Reynoso-Noverón, N., & Torres-Domínguez, J. A. (2018). Epidemiologíadel cáncer en México : carga global y proyecciones 2000-2020.Revista Latinoamericana de Medicina Conductual, 8(1), 9–15.

  27. Rojas-Puentes, L., De La Garza-Salazar, J. G., Calderillo-Ruíz, G., Lino-Silva,L. S., Vidal Millán, S., Reynoso Noverón, N., Meneses-García,A., Astudillo De La Vega, H., Betzabe Ruiz García, E., Betzabe, E.,& García, R. (2014). Increased Incidence of Colorrectal Cancer inYoung People (Less Than 40 Years Old) Over the Last Ten Years.Journal of Cancerology., 11, 16–22.

  28. Sánchez-Barriga, J. J. (2017). Tendencias de mortalidad y riesgo demuerte por cáncer colorrectal en las 7 regiones socioeconómicasde México, 2000-2012. Revista de Gastroenterologia de Mexico,82(3), 217–225. https://doi.org/10.1016/j.rgmx.2016.10.005

  29. Sinicrope, F. A., Shi, Q., Smyrk, T. C., Thibodeau, S. N., Dienstmann, R.,Guinney, J., Bot, B. M., Tejpar, S., Delorenzi, M., Goldberg, R. M., Mahoney,M., Sargent, D. J., & Alberts, S. R. (2015). Molecular markers identify subtypes of stage III colon cancer associated withpatient outcomes. Gastroenterology, 148(1), 88–99. https://doi.org/10.1053/j.gastro.2014.09.041

  30. Stürmer, T., Glynn, R. J., Lee, I. M., Manson, J. E., Buring, J. E., & Hennekens,C. H. (1998). Aspirin use and colorrectal cancer: post-trialfollow-up data from the Physicians’ Health Study. Annals of InternalMedicine, 128(9), 713–720. https://doi.org/10.7326/0003-4819-128-9-199805010-00003

  31. Thun, M. J., Namboodiri, M. M., & Heath, C. W. J. (1991). Aspirin useand reduced risk of fatal colon cancer. The New England Journalof Medicine, 325(23), 1593–1596. https://doi.org/10.1056/NEJM199112053252301

  32. Villegas-Mejía, C. R., Chacón-cardona, J. A., Villegas-jaramillo, M., & Villegas-Jaramillo, P. (2018). Cáncer de colon ¿ una sola entidad ?Consideraciones sobre lateralidad en una institución oncológicacolombiana 2001-2016. Ces Medicina, 1, 191–202. https://doi.org/http://dx.doi.org/10.21615/ cesmedicina.32.3.1




2020     |     www.medigraphic.com